Takeda Pharmaceutical is planning a $725 million overhaul of its research and development efforts.
United States Rep. Ted Lieu (D-Torrance) is urging Congress to tighten requirements governing medical device warnings, in light of the discovery that Olympus told U.S. executives not to issue a warning to hospitals regarding a possible deadly infection from tainted scopes.
Seres Therapeutics reported results from an interim phase 2 trial for its colon infection treatment. The results found the treatment was not statistically significant.
The FDA approved AbbVie’s new drug application for VIEKIRA XR extended-release tablets.
Galmed Pharmaceuticals named Ran Oren, MD, chief medical officer.
More articles on GI/endoscopy:
Dr. Kimberly Kolkhorst joins Essentia Health: 3 notes
Seres Therapeutics’ Phase 2 clinical trial results for C. Diff treatment not statistically significant; company stock plummets: 7 points
St. Mary’s Hospital settles lawsuit related to endoscopy death; investigation of gastroenterologist closed: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.